JP5476517B2 - ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法 - Google Patents

ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法 Download PDF

Info

Publication number
JP5476517B2
JP5476517B2 JP2008542473A JP2008542473A JP5476517B2 JP 5476517 B2 JP5476517 B2 JP 5476517B2 JP 2008542473 A JP2008542473 A JP 2008542473A JP 2008542473 A JP2008542473 A JP 2008542473A JP 5476517 B2 JP5476517 B2 JP 5476517B2
Authority
JP
Japan
Prior art keywords
antibody
cells
human
antibodies
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008542473A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518005A5 (cg-RX-API-DMAC7.html
JP2009518005A (ja
Inventor
愼一郎 加藤
ニュージェント，レイチェル ソロフ
均 吉田
クロフト，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38067974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5476517(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of JP2009518005A publication Critical patent/JP2009518005A/ja
Publication of JP2009518005A5 publication Critical patent/JP2009518005A5/ja
Application granted granted Critical
Publication of JP5476517B2 publication Critical patent/JP5476517B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
JP2008542473A 2005-11-25 2006-11-27 ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法 Active JP5476517B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73965905P 2005-11-25 2005-11-25
US60/739,659 2005-11-25
PCT/US2006/045522 WO2007062245A2 (en) 2005-11-25 2006-11-27 Human monoclonal antibody human cd134 (ox40) and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013161779A Division JP5802245B2 (ja) 2005-11-25 2013-08-02 ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法

Publications (3)

Publication Number Publication Date
JP2009518005A JP2009518005A (ja) 2009-05-07
JP2009518005A5 JP2009518005A5 (cg-RX-API-DMAC7.html) 2010-01-14
JP5476517B2 true JP5476517B2 (ja) 2014-04-23

Family

ID=38067974

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008542473A Active JP5476517B2 (ja) 2005-11-25 2006-11-27 ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法
JP2013161779A Active JP5802245B2 (ja) 2005-11-25 2013-08-02 ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013161779A Active JP5802245B2 (ja) 2005-11-25 2013-08-02 ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法

Country Status (17)

Country Link
US (5) US8283450B2 (cg-RX-API-DMAC7.html)
EP (4) EP1951760B2 (cg-RX-API-DMAC7.html)
JP (2) JP5476517B2 (cg-RX-API-DMAC7.html)
KR (1) KR101340699B1 (cg-RX-API-DMAC7.html)
CN (1) CN101331150B (cg-RX-API-DMAC7.html)
AU (1) AU2006318329B2 (cg-RX-API-DMAC7.html)
CA (1) CA2631015C (cg-RX-API-DMAC7.html)
DK (1) DK3345927T5 (cg-RX-API-DMAC7.html)
ES (3) ES2602263T5 (cg-RX-API-DMAC7.html)
FI (1) FI3345927T3 (cg-RX-API-DMAC7.html)
HU (3) HUE031037T2 (cg-RX-API-DMAC7.html)
LT (1) LT3345927T (cg-RX-API-DMAC7.html)
PL (3) PL3098238T3 (cg-RX-API-DMAC7.html)
PT (3) PT3098238T (cg-RX-API-DMAC7.html)
SI (1) SI3345927T1 (cg-RX-API-DMAC7.html)
TW (1) TWI461436B (cg-RX-API-DMAC7.html)
WO (1) WO2007062245A2 (cg-RX-API-DMAC7.html)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
MX2009009194A (es) * 2007-02-27 2009-10-08 Genentech Inc Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
MX2010006466A (es) * 2007-12-14 2010-09-28 Bristol Myers Squibb Co Moleculas de union al receptor ox40 de humano.
AU2016203429B2 (en) * 2007-12-14 2018-01-25 Bristol-Myers Squibb Company Binding Molecules to the Human OX40 Receptor
AU2014202213B2 (en) * 2007-12-14 2016-05-12 Bristol-Myers Squibb Company Binding Molecules to the Human OX40 Receptor
SG173620A1 (en) * 2009-02-17 2011-09-29 Ucb Pharma Sa Antibody molecules having specificity for human ox40
PH12013500354B1 (en) * 2010-08-23 2018-10-19 Univ Texas Anti-ox40 antibodies and methods of using the same
ES2720136T3 (es) * 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
BR112013031892A2 (pt) * 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
MX353931B (es) * 2011-07-11 2018-02-02 Glenmark Pharmaceuticals Sa Anticuerpos que se unen a ox40 y sus usos.
JP6038920B2 (ja) * 2011-08-23 2016-12-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013134365A1 (en) 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
US10259626B2 (en) 2012-03-08 2019-04-16 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
HUE043903T2 (hu) 2012-12-03 2019-09-30 Bristol Myers Squibb Co Immunmodulációs FC fúziós proteinek rákellenes aktivitásának javítása
EP2951209A4 (en) 2013-01-31 2016-06-22 Univ Jefferson CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
CN105229032A (zh) 2013-03-18 2016-01-06 比奥塞罗克斯产品公司 人源化抗cd134(ox40)抗体及其应用
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
JP6637439B2 (ja) * 2014-03-31 2020-01-29 ジェネンテック， インコーポレイテッド 抗ｏｘ４０抗体及び使用方法
RS61678B1 (sr) 2014-05-28 2021-05-31 Agenus Inc Anti-gitr antitela i postupci za njihovu primenu
EP3148573A4 (en) * 2014-05-29 2017-11-15 Medimmune, LLC Ox40l fusion proteins and uses thereof
AU2015301338C1 (en) 2014-08-04 2021-07-22 Baylor Research Institute Antagonistic anti-OX40L antibodies and methods of their use
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
IL284430B2 (en) 2015-01-20 2024-04-01 Igm Biosciences Inc Tumor necrosis factor-α receptor binding molecules and their uses
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
LT3265123T (lt) 2015-03-03 2023-01-25 Kymab Limited Antikūnai, naudojimas ir būdai
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
HUE061253T2 (hu) 2015-05-29 2023-06-28 Bristol Myers Squibb Co Antitestek OX40 ellen és azok felhasználásai
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
WO2017026532A1 (ja) * 2015-08-10 2017-02-16 国立大学法人富山大学 抗原特異的モノクローナル抗体作製方法
JP6904947B2 (ja) * 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
MY198560A (en) 2015-10-02 2023-09-05 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
US10624974B2 (en) * 2015-10-15 2020-04-21 Dingfu Biotarget Co., Ltd. Anti-OX40 antibody and application thereof
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
CN105483083B (zh) * 2016-01-20 2018-10-23 北京医明佳和生物科技有限公司 双阴性t细胞的转化扩增方法
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
HUE050399T2 (hu) * 2016-12-15 2020-12-28 Abbvie Biotherapeutics Inc Anti-OX40 antitestek és alkalmazásuk
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN108623685B (zh) * 2017-03-25 2022-07-01 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
BR112020010137A2 (pt) 2017-11-24 2020-10-13 Eucure (Beijing) Biopharma Co., Ltd anticorpos anti-ox40 e usos dos mesmos
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
CN110467674B (zh) * 2018-05-11 2022-05-31 同润澳门一人有限公司 抗ox40的全人抗体及其制备方法和用途
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
US10442866B1 (en) * 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP7655566B2 (ja) * 2019-07-08 2025-04-02 ニューヨーク ユニバーシティ シンドビスウイルスベクター及びアゴニストモノクローナル抗体を用いる腫瘍免疫療法
US20220324945A1 (en) 2019-07-31 2022-10-13 Kyowa Kirin Co., Ltd. Method for purifying antibody using adsorbent
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
JP2023545084A (ja) 2020-10-09 2023-10-26 協和キリン株式会社 Ｏｘ４０関連疾患を治療するための方法
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20220160512A (ko) * 2021-05-27 2022-12-06 주식회사유한양행 Ox40 작용제 및 그의 용도
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
EP4507779A1 (en) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
KR20250067128A (ko) 2022-09-15 2025-05-14 아비디큐어 아이피 비.브이. Nk 세포의 종양-표적화를 위한 다중특이적 항원 결합 단백질 및 이의 용도
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024100136A1 (en) 2022-11-08 2024-05-16 Gadeta B.V. Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN116036268A (zh) * 2023-03-02 2023-05-02 中南大学湘雅二医院 一种ox40l单克隆阻断抗体的应用
WO2025161898A1 (en) * 2024-02-02 2025-08-07 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ox40 antibodies and uses thereof
WO2025186778A1 (en) 2024-03-08 2025-09-12 Janssen Biotech, Inc. Combinations of oncolytic viruses and immunomodulators
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2562421B1 (fr) 1984-04-09 1989-02-17 Sandoz Sa Perfectionnements a la therapie par l'interleukine
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ATE68968T1 (de) 1985-11-22 1991-11-15 Takeda Chemical Industries Ltd Liposomzusammensetzung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
EP0572401B2 (en) 1991-02-19 2007-11-07 The Regents of the University of California Viral particles having altered host range
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
AU7353494A (en) 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
CA2446968C (en) 2001-05-11 2012-07-03 Kirin Beer Kabushiki Kaisha Human artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
US20040136992A1 (en) * 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
CN103709250B (zh) * 2002-10-17 2016-08-10 根马布股份公司 抗cd20的人单克隆抗体
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法

Also Published As

Publication number Publication date
EP1951760B2 (en) 2020-03-18
JP5802245B2 (ja) 2015-10-28
US9475878B2 (en) 2016-10-25
CN101331150A (zh) 2008-12-24
EP3345927B9 (en) 2023-04-12
KR20080080503A (ko) 2008-09-04
PL1951760T3 (pl) 2017-02-28
TWI461436B (zh) 2014-11-21
JP2014012003A (ja) 2014-01-23
EP1951760B1 (en) 2016-08-31
AU2006318329A1 (en) 2007-05-31
WO2007062245A2 (en) 2007-05-31
PT1951760T (pt) 2016-10-18
EP1951760A2 (en) 2008-08-06
CA2631015A1 (en) 2007-05-31
US20100196359A1 (en) 2010-08-05
US20170081417A1 (en) 2017-03-23
US20140044703A1 (en) 2014-02-13
PT3345927T (pt) 2023-02-28
FI3345927T3 (fi) 2023-03-30
PL3345927T3 (pl) 2023-05-29
TW200738748A (en) 2007-10-16
US9969810B2 (en) 2018-05-15
EP4219557A1 (en) 2023-08-02
JP2009518005A (ja) 2009-05-07
CA2631015C (en) 2015-11-17
LT3345927T (lt) 2023-02-10
EP3098238B1 (en) 2018-03-14
US20180298107A1 (en) 2018-10-18
HUE031037T2 (en) 2017-06-28
ES2667522T3 (es) 2018-05-11
PL3098238T3 (pl) 2018-07-31
US11192953B2 (en) 2021-12-07
US12319741B2 (en) 2025-06-03
CN101331150B (zh) 2012-06-13
ES2602263T5 (es) 2020-11-05
EP3345927B1 (en) 2023-01-11
HUE061960T2 (hu) 2023-09-28
EP3345927A1 (en) 2018-07-11
US20220064319A1 (en) 2022-03-03
EP3098238A1 (en) 2016-11-30
PL1951760T5 (pl) 2023-09-18
SI3345927T1 (sl) 2023-03-31
PT3098238T (pt) 2018-04-17
KR101340699B1 (ko) 2013-12-12
DK3345927T3 (da) 2023-03-27
AU2006318329B2 (en) 2011-09-22
HUE037642T2 (hu) 2018-09-28
DK3345927T5 (da) 2024-09-30
ES2602263T3 (es) 2017-02-20
HK1232230A1 (en) 2018-01-05
US8283450B2 (en) 2012-10-09
ES2938625T3 (es) 2023-04-13
WO2007062245A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
JP5476517B2 (ja) ヒトモノクローナル抗体ヒトｃｄ１３４（ｏｘ４０）ならびにその作製および使用方法
US8816058B2 (en) Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof
US12006365B2 (en) Human anti-semaphorin 4D antibody
US20240239907A1 (en) C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
HK1232230B (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
HK1124340B (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131022

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131121

R150 Certificate of patent or registration of utility model

Ref document number: 5476517

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250